An Efficacy Trial of The Toolkit for Optimal Recovery After Concussion (An efficacy tr)
The goal of this study is to test the efficacy of the Toolkit for Optimal Recovery after Concussion (TOR-C), a brief live-video mind-body program. aiming to prevent chronic concussion symptoms and optimize recovery.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02114
- Mass General Brigham
-
Kontakt:
- Jonathan Greenberg
- Telefonnummer: 617-643-9402
- E-Mail: MGHConcusionToolkit@partners.org
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Sustained a concussion 3-10 weeks earlier
- At least mild anxiety symptoms (score ≥ 5 on GAD-7 anxiety scale)
- Age 18-35
- English fluency and literacy
- Ability and willingness to participate in study procedures, assessments, and intervention
- Access to a smartphone or computer with internet access
- Cleared for participation by clinic/study staff
Exclusion Criteria:
- Participation in mind-body or CBT treatment in the past 3 months
- Concussion in the past 2 years that resulted in symptoms lasting 3 months or more / current or previous complicated or moderate/severe TBI
- Practice of mindfulness techniques > 45 minutes/week in the past 3 months
- Change in psychotropic medications (e.g., antidepressant, anxiolytics) in the past 6 weeks
- Uncontrolled bipolar disorder, psychosis, active substance dependence, self reported current active suicidal ideation with plan and/or intent
- Pregnancy
- Serious comorbidity expected to worsen in the next 6 months
- Secondary gains that may bias motivation (e.g., pending disability claim)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Toolkit for Optimal Recovery after Concussion (TOR-C)
A 4-week mind-body program delivered via live video (Zoom) 1:1 with a clinician delivering mind-body and cognitive-behavioral skills. |
TOR-C is a brief behavioral mind-body program delivered remotely via live video over four weekly 45-minute sessions, with approximately 10 minutes of daily home practice. It targets anxiety and fear-avoidance factors to prevent chronic concussion symptoms, combining mind-body skills (e.g., mindfulness, deep breathing, acceptance), light cognitive-behavioral skills, skills for gradual return to activity, and concussion psychoeducation. |
|
Aktiver Komparator: Health Enhancement after Concussion (HE-C)
A 4-week program delivered via live video (Zoom) 1:1 with a clinician delivering psychoeducation and information about healthy living after a concussion |
HE-C is an attention-matched active control program delivered remotely via live video over four weekly 45-minute sessions, with approximately 10 minutes of daily home practice. It provides general health education after concussion (e.g., sleep, nutrition, physical activity) without the specific skills included in TOR-C. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Post-Concussion Symptom Scale (PCSS)
Zeitfenster: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
Measures the severity of concussion symptoms (e.g., headache, fatigue, dizziness, difficulty concentrating). This is the study's primary outcome; efficacy is judged mainly on reducing these symptoms. |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Generalized Anxiety Disorder scale (GAD-7)
Zeitfenster: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
Measures the severity of anxiety symptoms. (Also used at screening, where a score ≥5 is required for eligibility.) |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
|
Patient Health Questionnaire-9 (PHQ-9)
Zeitfenster: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
Measures the severity of depression symptoms. |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
|
Fear Avoidance Behavior after Traumatic Brain Injury (FAB-TBI)
Zeitfenster: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
Measures fear-avoidance behavior, i.e., avoiding activities out of fear they will worsen symptoms. A core mechanism in the fear-avoidance model. |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
|
Symptom Catastrophizing Scale
Zeitfenster: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
Measures the tendency to catastrophize concussion symptoms (magnifying, ruminating on, or feeling helpless about them). |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
|
Cognitive and Affective Mindfulness Scale-Revised (CAMS-R)
Zeitfenster: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
Measures mindfulness, i.e., present-moment awareness and acceptance of thoughts and feelings. |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
|
Behavioral Response to Illness Questionnaire (BRIQ): Limiting behavior subscale
Zeitfenster: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
Measures the tendency to limit or avoid various activities in response to medical conditions |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
|
Pittsburgh Sleep Quality Index (PSQI)
Zeitfenster: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
An exploratory outcome which measures sleep quality over the past month. |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
|
PROMIS Cognitive Function
Zeitfenster: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
An exploratory outcome which measures self-reported cognitive function (e.g., perceived problems with memory, attention, and thinking). |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
|
WHO Disability Assessment Schedule (WHODAS 2.0; 12-item version)
Zeitfenster: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
It is 12-item measure of health-related functioning and disability across daily activities (e.g., cognition, mobility, self-care, social participation) over the past 30 days, with higher scores indicating greater disability. |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Greenberg J, Singh T, Iverson GL, Silverberg ND, Macklin EA, Parker RA, Giacino JT, Yeh GY, Vranceanu AM. A Live Video Mind-Body Treatment to Prevent Persistent Symptoms Following Mild Traumatic Brain Injury: Protocol for a Mixed Methods Study. JMIR Res Protoc. 2021 Jan 14;10(1):e25746. doi: 10.2196/25746.
- Greenberg J, Levey NS, Becker M, Yeh GY, Giacino JT, Iverson G, Silverberg ND, Parker RA, Vranceanu AM. Feasibility Randomized Controlled Trial of the Toolkit for Optimal Recovery After Concussion: A Live Video Program to Prevent Persistent Concussion Symptoms in Young Adults With Anxiety. Arch Phys Med Rehabil. 2025 Apr;106(4):527-536. doi: 10.1016/j.apmr.2024.10.011. Epub 2024 Nov 5.
- Becker ME, Stratton Levey N, Yeh GY, Giacino J, Iverson G, Silverberg N, Parker RA, McKinnon E, Siravo C, Shah P, Vranceanu AM, Greenberg J. Preliminary Feasibility of a Novel Mind-Body Program to Prevent Persistent Concussion Symptoms Among Young Adults With Anxiety: Nonrandomized Open Pilot Study. JMIR Form Res. 2024 Nov 8;8:e64540. doi: 10.2196/64540.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Hirnverletzungen, traumatisch
- Erkrankungen des Gehirns
- Erkrankungen des zentralen Nervensystems
- Erkrankungen des Nervensystems
- Psychische Störungen
- Wunden und Verletzungen
- Pathologische Prozesse
- Kraniozerebrales Trauma
- Trauma, Nervensystem
- Kopfverletzungen, geschlossen
- Wunden, nicht durchdringend
- Hirnverletzungen
- Pathologische Zustände, Anzeichen und Symptome
- Angststörungen
- Erkrankung
- Gehirnerschütterung
- Post-Concussion-Syndrom
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 2026P002591
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
We plan to share our study protocol, analysis plan, data dictionary, and de-identified data from all measures described under "outcome measures"
IPD-Sharing-Zeitrahmen
Data from this study will be deposited into the Vivli database no later than one year of the completion of the funded project period
IPD-Sharing-Zugriffskriterien
Interested parties can create an account in the Vivli Database and submit a request to access study data
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .